897. Prevention of RSV in Children: Vaccines and Immunoprophylaxis
Session: Symposium: Advances in RSV Prevention
Friday, October 5, 2018: 8:45 AM
Room: N 24
Janet Englund, MD, FIDSA, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Pediatrics, Seattle Children's Hospital, Seattle, WA

Janet Englund, MD, is Professor of Pediatrics at the University of Washington, Seattle Children’s Hospital in Seattle, Washington. She is an affiliate investigator in the Clinical Research Division at Fred Hutchinson Cancer Research Center, Seattle, where she is active in transplant-related protocols in the prevention and treatment of disease in the immunocompromised host. Dr Englund earned her medical degree at University of Michigan Medical School and completed her residency in pediatrics, and fellowships in virology and pediatric infectious diseases at the University of Minnesota Medical School. She has served on many committees and advisory groups for immunization and respiratory viruses including the World Health Organization, Bill and Melinda Gates Foundation, US FDA Advisory Committee for Vaccines and Related Biological Products, the Advisory Committee on immunization Practices for the US Centers for Disease Control, and the IDSA Expert Panel on Seasonal Influenza in Adults and Children. Dr. Englund is actively studying new and current respiratory viral vaccines in diverse populations, including infants, school-age children and pregnant women, as well as evaluating viral diagnostics, antiviral resistance, and novel antiviral therapy. She directs the Seattle site of the CDC-sponsored New Vaccine Surveillance Network, where she studies influenza and rotavirus vaccine effectiveness and RSV and influenza epidemiology.


J. Englund, Medimmune: Investigator , Research support . Novavax: Investigator , Research support . Chimerix: Investigator , Research support . Gilead: Scientific Advisor , Consulting fee . Janssen: Investigator , Research support . Sanofi: Consultant , Consulting fee .

See more of: Advances in RSV Prevention
See more of: Symposium
Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.